Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

作者：Catalano V^*; Loupakis F; Graziano F; Torresi U; Bisonni R; Mari D; Fornaro L; Baldelli A M; Giordani P; Rossi D; Alessandroni P; Giustini L; Silva R R; Falcone A; D'Emidio S; Fedeli S L

来源：British Journal of Cancer, 2009, 100(6): 881-887.

DOI：10.1038/sj.bjc.6604955

• mucinous
• colorectal cancer
• chemotherapy
• irinotecan
• oxaliplatin
• 5-fluorouracil

The objective of this study was to investigate the efficacy of first-line chemotherapy containing irinotecan and/or oxaliplatin in patients with advanced mucinous colorectal cancer. Prognostic factors associated with response rate and survival were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. The population included 255 patients, of whom 49 (19%) had mucinous and 206 (81%) had non-mucinous colorectal cancer. The overall response rates for mucinous and non-mucinous tumours were 18.4 (95% CI, 7.5-29.2%) and 49% (95% CI, 42.2-55.8%), respectively (P = 0.0002). After a median follow-up of 45 months, median overall survival for the mucinous patients was 14.0 months compared with 23.4 months for the non-mucinous group (hazard ratio (HR), 1.74; CI 95%, 1.27 - 3.31; P = 0.0034). After adjustment for significant features by multivariate Cox regression analysis, mucinous histology was associated with poor overall survival (HR, 1.593, 95% CI, 1.05 - 2.40; P = 0.0267), together with performance status ECOG 2, number of metastatic sites >= 2, and peritoneal metastases. This retrospective analysis shows that patients with mucinous colorectal cancer have poor responsiveness to oxaliplatin/irinotecan-based first-line combination chemotherapy and an unfavourable prognosis compared with non-mucinous colorectal cancer patients.

• 出版日期2009-3-17